Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein cholesterol (HDL-C). The company was founded in 2019 and is based in Naarden, the Netherlands.

NewAmsterdam Pharma Company N.V.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

NAARDEN, THE NETHERLANDS AND MIAMI, SEPT. 03, 2026 (GLOBE NEWSWIRE) -- NEWAMSTERDAM PHARMA COMPANY N.V. (NASDAQ: NAMS OR NEWAMSTERDAM OR THE COMPANY), A LATE-STAGE, CLINICAL BIOPHARMACEUTICAL COMPANY DEVELOPING ORAL, NON-STATIN MEDICINES FOR PATIENTS AT RISK OF CARDIOVASCULAR DISEASE (CVD) WITH ELEVATED LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C), FOR WHOM EXISTING THERAPIES ARE NOT SUFFICIENTLY EFFECTIVE OR WELL-TOLERATED, TODAY ANNOUNCED THAT THE COMPENSATION COMMITTEE OF NEWAMSTERDAM'S BOARD OF DIRECTORS APPROVED THE GRANT OF INDUCEMENT SHARE OPTIONS COVERING AN AGGREGATE OF 38,900 OF NEWAMSTERDAM'S ORDINARY SHARES TO FIVE NON-EXECUTIVE NEW HIRES, AS WELL AS INDUCEMENT SHARE OPTIONS COVERING 14,000 ORDINARY SHARES TO ROBERT GUNNING, THE COMPANY'S NEW VICE PRESIDENT, CONTROLLER, WHO SERVES AS THE COMPANY'S PRINCIPAL ACCOUNTING OFFICER. THE SHARE OPTIONS WERE GRANTED AS AN INDUCEMENT MATERIAL TO THE EMPLOYEES' ACCEPTANCE OF EMPLOYMENT WITH NEWAMSTERDAM PURSUANT TO THE NEWAMSTERDAM PHARMA COMPANY N.V. 2024 INDUCEMENT PLAN (THE 2024 INDUCEMENT PLAN) AND IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

NEWAMSTERDAM PHARMA REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

NAARDEN, THE NETHERLANDS AND MIAMI, SEPT. 02, 2026 (GLOBE NEWSWIRE) -- NEWAMSTERDAM PHARMA COMPANY N.V.

NEWAMSTERDAM PHARMA TO PARTICIPATE AT UPCOMING INVESTOR CONFERENCES IN SEPTEMBER

NAARDEN, THE NETHERLANDS AND MIAMI, AUG. 26, 2026 (GLOBE NEWSWIRE) -- NEWAMSTERDAM PHARMA COMPANY N.V. (NASDAQ: NAMS OR NEWAMSTERDAM OR THE COMPANY), A LATE-STAGE, CLINICAL BIOPHARMACEUTICAL COMPANY DEVELOPING ORAL, NON-STATIN MEDICINES FOR PATIENTS AT RISK OF CARDIOVASCULAR DISEASE (CVD) WITH ELEVATED LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C), FOR WHOM EXISTING THERAPIES ARE NOT SUFFICIENTLY EFFECTIVE OR WELL-TOLERATED, TODAY ANNOUNCED THAT IT WILL PRESENT DATA FROM ITS OBICETRAPIB DEVELOPMENT PROGRAM AT THE EUROPEAN SOCIETY OF CARDIOLOGY (ESC) CONGRESS 2026, TAKING PLACE AUGUST 28  31, 2026 IN MUNICH, GERMANY.

NEWAMSTERDAM PHARMA ANNOUNCES UPCOMING PRESENTATIONS AT THE EUROPEAN SOCIETY OF CARDIOLOGY (ESC) CONGRESS 2026

 ANNOUNCED POSITIVE CHMP OPINION RECOMMENDING MARKETING AUTHORIZATION FOR OBICETRAPIB AND OBICETRAPIB/EZETIMIBE   PREVAIL INTERIM ANALYSIS PLANNED FOR 4Q2026 WITH RESULT EXPECTED IN 1Q2027   TOPLINE DATA FROM RUBENS PHASE 3 EXPECTED BY YEAR-END 2026   $678.3 MILLION IN CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES AT JUNE 30, 2026   COMPANY TO HOST INVESTOR DAY TODAY AT 9:00 AM ET IN NEW YORK CITY  NAARDEN, THE NETHERLANDS AND MIAMI, AUG. 05, 2026 (GLOBE NEWSWIRE) -- NEWAMSTERDAM PHARMA COMPANY N.V. (NASDAQ: NAMS OR NEWAMSTERDAM OR THE COMPANY), A LATE-STAGE, CLINICAL BIOPHARMACEUTICAL COMPANY DEVELOPING ORAL, NON-STATIN MEDICINES FOR PATIENTS AT RISK OF CARDIOVASCULAR DISEASE (CVD) WITH ELEVATED LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C), FOR WHOM EXISTING THERAPIES ARE NOT SUFFICIENTLY EFFECTIVE OR WELL-TOLERATED, TODAY ANNOUNCED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2026 AND PROVIDED A CORPORATE UPDATE.

NEWAMSTERDAM PHARMA PROVIDES CORPORATE UPDATE AND REPORTS SECOND QUARTER FINANCIAL RESULTS

NAARDEN, THE NETHERLANDS AND MIAMI, JULY 29, 2026 (GLOBE NEWSWIRE) -- NEWAMSTERDAM PHARMA COMPANY N.V. (NASDAQ: NAMS OR NEWAMSTERDAM OR THE COMPANY), A LATE-STAGE, CLINICAL BIOPHARMACEUTICAL COMPANY DEVELOPING ORAL, NON-STATIN MEDICINES FOR PATIENTS AT RISK OF CARDIOVASCULAR DISEASE (CVD) WITH ELEVATED LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C), FOR WHOM EXISTING THERAPIES ARE NOT SUFFICIENTLY EFFECTIVE OR WELL-TOLERATED, TODAY ANNOUNCED THAT IT WILL HOST AN INVESTOR DAY EVENT FOR ANALYSTS AND INVESTORS ON AUGUST 5, 2026 BEGINNING AT 9:00 A.M. ET IN NEW YORK CITY.

NEWAMSTERDAM PHARMA TO HOST INVESTOR DAY ON AUGUST 5, 2026

- POSITIVE CHMP OPINION SUPPORTS POTENTIAL COMMERCIALIZATION OF OBICETRAPIB MONOTHERAPY AND OBICETRAPIB/EZETIMIBE FIXED-DOSE COMBINATION IN EUROPE - - RECOMMENDATION BASED ON POSITIVE PHASE 3 BROADWAY, BROOKLYN, AND TANDEM DATA - - EUROPEAN COMMISSION DECISION EXPECTED IN 2H26 - NAARDEN, THE NETHERLANDS AND MIAMI AND FLORENCE, ITALY, JULY 24, 2026 (GLOBE NEWSWIRE) -- NEWAMSTERDAM PHARMA COMPANY N.V. (NASDAQ: NAMS OR NEWAMSTERDAM OR THE COMPANY), A LATE-STAGE, CLINICAL BIOPHARMACEUTICAL COMPANY DEVELOPING ORAL, NON-STATIN MEDICINES FOR PATIENTS AT RISK OF CARDIOVASCULAR DISEASE (CVD) WITH ELEVATED LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C), FOR WHOM EXISTING THERAPIES ARE NOT SUFFICIENTLY EFFECTIVE OR WELL-TOLERATED, ALONG WITH PARTNER MENARINI GROUP (MENARINI), TODAY ANNOUNCED THAT THE COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) OF THE EUROPEAN MEDICINES AGENCY (EMA) HAS ADOPTED A POSITIVE OPINION RECOMMENDING MARKETING AUTHORIZATION FOR UBESLO (OBICETRAPIB 10 MG MONOTHERAPY) AND EVLARCO (10 MG OBICETRAPIB PLUS 10 MG EZETIMIBE FIXED-DOSE COMBINATION (FDC)) FOR PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, BOTH HETEROZYGOUS FAMILIAL (HEFH) AND NON-FAMILIAL OR MIXED DYSLIPIDEMIA.

NEWAMSTERDAM PHARMA AND MENARINI GROUP RECEIVE POSITIVE CHMP OPINION RECOMMENDING MARKETING AUTHORIZATION FOR UBESLO (OBICETRAPIB MONOTHERAPY) AND EVLARCO (OBICETRAPIB PLUS EZETIMIBE FIXED-DOSE COMBINATION)

NAARDEN, THE NETHERLANDS AND MIAMI, JULY 02, 2026 (GLOBE NEWSWIRE) -- NEWAMSTERDAM PHARMA COMPANY N.V. (NASDAQ: NAMS OR NEWAMSTERDAM OR THE COMPANY), A LATE-STAGE, CLINICAL BIOPHARMACEUTICAL COMPANY DEVELOPING ORAL, NON-STATIN MEDICINES FOR PATIENTS AT RISK OF CARDIOVASCULAR DISEASE (CVD) WITH ELEVATED LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C), FOR WHOM EXISTING THERAPIES ARE NOT SUFFICIENTLY EFFECTIVE OR WELL-TOLERATED, TODAY ANNOUNCED THAT THE COMPENSATION COMMITTEE OF NEWAMSTERDAM'S BOARD OF DIRECTORS APPROVED THE GRANT OF INDUCEMENT SHARE OPTIONS COVERING AN AGGREGATE OF 28,700 OF NEWAMSTERDAM'S ORDINARY SHARES TO FOUR NON-EXECUTIVE NEW HIRES.

NAARDEN, THE NETHERLANDS AND MIAMI, JULY 01, 2026 (GLOBE NEWSWIRE) -- NEWAMSTERDAM PHARMA COMPANY N.V. (NASDAQ: NAMS OR NEWAMSTERDAM OR THE COMPANY), A LATE-STAGE, CLINICAL BIOPHARMACEUTICAL COMPANY DEVELOPING ORAL, NON-STATIN MEDICINES FOR PATIENTS AT RISK OF CARDIOVASCULAR DISEASE (CVD) WITH ELEVATED LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C), FOR WHOM EXISTING THERAPIES ARE NOT SUFFICIENTLY EFFECTIVE OR WELL-TOLERATED, TODAY ANNOUNCED THAT IT WILL PRESENT DATA HIGHLIGHTING THE POTENTIAL FOR OBICETRAPIB AS A NOVEL, ORAL, LOW-DOSE THERAPY FOR THE PREVENTION OF EARLY ALZHEIMER'S DISEASE, AT THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2026, TAKING PLACE ON JULY 12  15, 2026 IN LONDON, UNITED KINGDOM.

NEWAMSTERDAM PHARMA ANNOUNCES UPCOMING PRESENTATIONS AT THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2026

NAARDEN, THE NETHERLANDS AND MIAMI, JUNE 03, 2026 (GLOBE NEWSWIRE) -- NEWAMSTERDAM PHARMA COMPANY N.V. (NASDAQ: NAMS OR NEWAMSTERDAM OR THE COMPANY), A LATE-STAGE, CLINICAL BIOPHARMACEUTICAL COMPANY DEVELOPING ORAL, NON-STATIN MEDICINES FOR PATIENTS AT RISK OF CARDIOVASCULAR DISEASE (CVD) WITH ELEVATED LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C), FOR WHOM EXISTING THERAPIES ARE NOT SUFFICIENTLY EFFECTIVE OR WELL-TOLERATED, TODAY ANNOUNCED THAT IT WILL PRESENT DATA HIGHLIGHTING THE POTENTIAL FOR OBICETRAPIB AS A NOVEL, ORAL, LOW-DOSE THERAPY FOR HYPERCHOLESTEROLEMIA, AT THE NATIONAL LIPID ASSOCIATION (NLA) 2026 SCIENTIFIC SESSIONS, TAKING PLACE ON JUNE 11  14, 2026 IN CHICAGO, ILLINOIS.

NEWAMSTERDAM PHARMA ANNOUNCES UPCOMING PRESENTATIONS AT THE NATIONAL LIPID ASSOCIATION (NLA) 2026 SCIENTIFIC SESSIONS

NAARDEN, THE NETHERLANDS AND MIAMI, MAY 28, 2026 (GLOBE NEWSWIRE) -- NEWAMSTERDAM PHARMA COMPANY N.V. (NASDAQ: NAMS OR NEWAMSTERDAM OR THE COMPANY), A LATE-STAGE, CLINICAL BIOPHARMACEUTICAL COMPANY DEVELOPING ORAL, NON-STATIN MEDICINES FOR PATIENTS AT RISK OF CARDIOVASCULAR DISEASE (CVD) WITH ELEVATED LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C), FOR WHOM EXISTING THERAPIES ARE NOT SUFFICIENTLY EFFECTIVE OR WELL-TOLERATED, TODAY ANNOUNCED THAT COMPANY MANAGEMENT WILL PARTICIPATE IN THE FOLLOWING UPCOMING INVESTOR CONFERENCES:

NewAmsterdam Pharma Company N.V.

NAMS

Price

Financial Reports

No items found.

Press Releases

NewAmsterdam Pharma Company N.V.

NAMS.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

NAMS